Who is sponsoring NCT02259361?

NCT02259361 is sponsored by Sheba Medical Center.

What condition does NCT02259361 study?

NCT02259361 studies Multiple Sclerosis.

What drugs are being tested in NCT02259361?

Interventions: Sustained-release oral dalfampridine, Placebo.

What is the status of NCT02259361?

NCT02259361 is currently UNKNOWN.

Last reviewed 2014-10-05 · How we verify

Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study

NCT02259361 Phase 4 UNKNOWN

This study evaluates the effects of sustained-release oral dalfampridine in the treatment of upper limb deficits in people with multiple sclerosis (MS). In this double-blind randomized pilot study half of participants will dalfampridine, while the other half will receive a placebo.

Details

Lead sponsor	Sheba Medical Center
Phase	Phase 4
Status	UNKNOWN
Enrolment	30
Start date	2014-11
Completion	2014-11

Conditions

Multiple Sclerosis

Interventions

Sustained-release oral dalfampridine
Placebo

Primary outcomes

Nine-Hole Peg Test — Changes in the Nine-Hole Peg Test from Baseline to end of Second week
The Nine-Hole Peg Test is a brief, standardized, quantitative test of upper extremity function
Nine-Hole Peg Test — Changes in the Nine-Hole Peg Test from Baseline to end of first week
The Nine-Hole Peg Test is a brief, standardized, quantitative test of upper extremity function
Nine-Hole Peg Test — Changes in the Nine-Hole Peg Test from end of second week to follow up 2-weeks after end of intervention phase
The Nine-Hole Peg Test is a brief, standardized, quantitative test of upper extremity function

Countries

Israel